Search
Tools content (print, share, increase/decrease text size):
-
Size
Middle area:Press releases 2007Press releases are intended to journalists, analysts and investors. Taxotere®-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy In Early Stage Breast CancerDecember 13, 2007 New anti-thrombotic compound AVE5026 shows highly significant dose response in TREK phase IIb studyDecember 10, 2007 Sanofi-aventis inaugurates first Asian development centre for pharmaceuticals in Goa, IndiaDecember 03, 2007 Sanofi-aventis and Astellas to restructure the joint venture activities in Japan of Fujisawa sanofi-aventis K.K.November 30, 2007 Sanofi-aventis initiates a major global collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19 %November 29, 2007 Sanofi-aventis to build a vaccine facility in Shenzhen for prevention of influenza and pandemic readiness in ChinaNovember 26, 2007 Rimonabant - Bibliographical updateNovember 16, 2007 Rimonabant - Regulatory Update in EuropeNovember 13, 2007 Sanofi Pasteur and Acambis join forces to bring West Nile vaccine to marketNovember 13, 2007 New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort® AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic RhinitisNovember 10, 2007 Retrospective Analysis Finds that Initiation of Insulin Glargine in Patients with Type 2 Diabetes was Associated with a Lower Incidence Rate of Myocardial Infarction as Compared with NPH InsulinNovember 07, 2007 Coarsucam™/“ASAQ” is as Effective as Coartem® in Treating Uncomplicated MalariaNovember 07, 2007 Sanofi Pasteur initiates phase II trial of cell culture-based seasonal influenza vaccineNovember 07, 2007 Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccineNovember 06, 2007 Good third quarter performance: increase in 2007 full-year earnings growth guidanceOctober 31, 2007 Studies Showing Significant Survival Improvement with Taxotere®-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of The New England Journal of MedicineOctober 24, 2007 New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR® (zolpidem tartrate extended-release) tabletsOctober 24, 2007 Taxotere® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for induction treatment for locally advanced Head and Neck cancerOctober 22, 2007 Plavix® indications expanded in Japan to include patients with Acute Coronary Syndrome for whom percutaneous coronary intervention is being plannedOctober 22, 2007 Sanofi Pasteur receives FDA approval of meningococcal vaccine for childrenOctober 18, 2007 Sanofi Pasteur and Institut Pasteur team up against malariaOctober 15, 2007 New prescription allergy treatment XYZAL® (levocetirizine dihydrochloride) now available for fall allergy season in the USAOctober 02, 2007 Taxotere® (docetaxel) granted FDA approval to treat Locally Advanced Head and Neck Cancer prior to chemoradiotherapy and surgeryOctober 01, 2007 Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World)September 24, 2007 Appropriate glycemic control contributes to reducing the risk of macrovascular diseases in patients with diabetesSeptember 19, 2007 Rimonabant effectively reduces visceral fat in the obese patient as confirmed by abdominal computer tomography (CT) scanSeptember 19, 2007 A promising R&D portfolio, well positioned to deliver future growthSeptember 17, 2007 Sanofi-aventis initiates Research collaboration in China in the cancer stem-cell fieldSeptember 14, 2007 Sanofi-aventis announces settlement of Average Wholesale Price Civil Suits with the U.S. Department of Justice relating to Anzemet®September 10, 2007 The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With No Observed Pro-ArrhythmiaSeptember 05, 2007 Survival Benefit of Taxotere®-Based Regimens In Patients With Non Small Cell Lung CancerSeptember 04, 2007 New Study Findings Confirm CLEXANE®/LOVENOX® Long-Term Clinical Benefit In Patients Suffering From Acute Coronary SyndromeSeptember 03, 2007 Availability on line of the Group’s half-year financial report for 2007August 02, 2007 First half: solid results in a difficult context. Plavix® recovers its position in the US, full impact expected in H2August 01, 2007 Sanofi pasteur President and CEO David J. Williams to retire; Wayne Pisano named President and CEOJuly 26, 2007 Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facilityJuly 20, 2007 CHMP approves labelling update of Acomplia® in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depressionJuly 19, 2007 Idraparinux shows encouraging results in the prevention of thromboembolic events in patients with atrial fibrillationJuly 11, 2007 New study shows that extending prophylaxis with Clexane®/ Lovenox® (enoxaparin sodium injection) to 5 weeks is more effective than 10 days for reducing the risk of venous thromboembolism (VTE) in acutely ill medical patients with reduced mobilityJuly 08, 2007 Plavix® (clopidogrel bisulfate) receives priority review in Japan for supplemental new drug application (sNDA) for The treatment of acute coronary syndromeJuly 04, 2007 Rimonabant Regulatory Update in the United StatesJune 29, 2007 Taxotere® (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and SurgeryJune 27, 2007 Apidra® Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin And Oral Antidiabetic Treatments (BOT)June 24, 2007 For any given level of HbA1c, Lantus® demonstrates less confirmed hypoglycemia over Insulin NPHJune 23, 2007 Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus® Lowered Free Fatty Acid Levels Equal to or Better Than ThiazolidinedionesJune 23, 2007 Sanofi-aventis and Bristol-Myers Squibb Prevail in U.S. Plavix® Patent LitigationJune 19, 2007 Sanofi pasteur awarded contract to retrofit influenza vaccine facilityJune 14, 2007 FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factorsJune 13, 2007 Sanofi pasteur supports WHO initiative for the establishment of an H5N1 vaccine stockpileJune 13, 2007 Taxotere® (docetaxel) receives Priority Review in Japan for Supplemental New Drug Application (sNDA) in prostate cancerJune 07, 2007 Sanofi-aventis at the 43rd annual 2007 ASCO meetingJune 06, 2007 Copaxone® pre-filled syringe can now be stored for up to one month at room temperatureJune 06, 2007 Eloxatin® (oxaliplatin injection)-based chemotherapy sets new treatment benchmark in patients with metastatic colorectal cancerJune 04, 2007 The Eloxatin®-based regimen (FOLFOX4) significantly improved progression free survival when given before and after surgery in patients with resectable liver metastases from colorectal cancerJune 04, 2007 Oxford BioMedica and Sanofi-aventis report encouraging new TroVax® phase II trial results in renal cancerJune 03, 2007 S-1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S-1 aloneJune 03, 2007 FOLFOX4 (Eloxatin®-based chemotherapy) after surgery improves overall survival in patients with early (stage III) colon cancerJune 03, 2007 “My child matters” one-year report program shows measurable improvement in cancer care for children in developing and newly industrialized countriesJune 03, 2007 Encouraging results of VEGF Trap (Aflibercept) highlighted at ASCO 2007 annual meetingJune 02, 2007 FDA approves XYZAL® tablets for the treatment of seasonal and year round allergies, and chronic urticariaMay 29, 2007 Data to be presented at ASCO 2007 highlights sanofi-aventis commitment to oncologyMay 25, 2007 FDA approves Lovenox® (Enoxaparin Sodium Injection) for the most severe type of heart attackMay 18, 2007 Sanofi-aventis calls for an effective policy against drug counterfeitingMay 15, 2007 Full-year guidance raised on good 2007 first-quarter resultsMay 03, 2007 FDA Approves SoloSTAR® - A New Prefilled Disposable Insulin Pen For Use With LANTUS® In People With Type 1 And Type 2 DiabetesApril 30, 2007 Information relating to sanofi-aventis’ Combined General Meeting of May 31, 2007April 26, 2007 Acomplia® (rimonabant) is approved in Brazil for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidemiaApril 26, 2007 ACOMPLIA® (rimonabant) is reimbursed in Switzerland for the treatment of Type 2 Diabetics Overweight Patients and for the treatment of Patients with ObesityApril 24, 2007 The Lancet Publishes PREVAIL Study Results Showing Lovenox® Superiority Over Unfractionated Heparin For Reducing The Risk Of Venous Thromboembolism In Patients With Acute Ischemic StrokeApril 20, 2007 FDA Licenses First U.S. Vaccine for Humans Against Avian InfluenzaApril 17, 2007 Filing of the 2006 U.S. Form 20-F and French "Document de Référence"April 03, 2007 Acomplia® (rimonabant) approved in Switzerland for the treatment of obese and overweight patients with at least one cardiovascular risk factorApril 03, 2007 Panaldine® commercial rights transferred from Daiichi to sanofi-aventis in JapanApril 02, 2007 Sanofi-aventis Announces Update To The European Summary Of Product Characteristics (SmPC) For Ketek® (telithromycin)March 30, 2007 Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For CancerMarch 28, 2007 Acomplia® (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patientsMarch 22, 2007 LANTUS®SoloSTAR® and APIDRA®SoloSTAR® – New Disposable Insulin Pens for People with Type 1 and Type 2 Diabetes Will Be Launched Starting April 2007 in EuropeMarch 16, 2007 Sanofi-aventis' commitment to providing "Access to Medicines" in countries in the Southern Hemisphere shows real achievementsMarch 12, 2007 New, Once-a-Day Fixed-Dose Combination Against Malaria Now AvailableMarch 01, 2007 Taxotere® (docetaxel) significantly improves the survival of patients with advanced prostate cancerFebruary 23, 2007 Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine from AcambisFebruary 14, 2007 2006: In a difficult environment, another year of growth in adjusted EPS excluding selected itemsFebruary 13, 2007 Sanofi-aventis announces update to US Prescribing Information for Ketek® (telithromycin)February 12, 2007 LOVENOX® patent infringement suit decided against Sanofi-aventisFebruary 09, 2007 FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attackFebruary 06, 2007 Positive Recommendation for Acomplia® from the Transparency Committee in FranceFebruary 06, 2007 "My child matters": 26 programmes launched in 16 countries to fight childhood cancersFebruary 01, 2007 FDA Advisory Committee Recommends Licensure of New Pediatric Combination VaccineJanuary 25, 2007 S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery aloneJanuary 19, 2007 Sanofi-aventis intends to contest in court the decision to classify Acomplia® among non-reimbursable drugs in GermanyJanuary 12, 2007 New Head of Research & Development at sanofi-aventisJanuary 05, 2007 |
Tools menu:
© Sanofi 2004-2013 - All rights reserved - Update: January 28, 2013
